TSW
VIVO

Thompson Siegel & Walmsley’s Meridian Bioscience Inc VIVO Stock Holding History

Thompson Siegel & Walmsley’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-143
Closed -$3K – 975
2016
Q4 		$3K Buy
+143
New +$2.51K ﹤0.01% 749

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Thompson Siegel & Walmsley's VIVO Position: Q1 2017 in Review

Thompson Siegel & Walmsley sold out of Meridian Bioscience Inc (VIVO) in Q1 2017, closing a stake of 143 shares — an estimated $3K sold.

Thompson Siegel & Walmsley first reported a position in VIVO in Q4 2016 and held it in 1 quarter. The position peaked at $3K in Q4 2016. 165 funds tracked by Wall St. Rank hold VIVO as of Q1 2017.

  • Thompson Siegel & Walmsley reported no remaining Meridian Bioscience Inc position as of Q1 2017 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 143 Meridian Bioscience Inc shares in Q1 2017, an estimated $3K.
  • Thompson Siegel & Walmsley first reported a position in Meridian Bioscience Inc in Q4 2016 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's Meridian Bioscience Inc position peaked at $3K in Q4 2016.
  • 165 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2017.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2017, filed 15 May 2017.